# reload+after+2024-01-20 18:43:09.375750
address1§259 Liberty Avenue
city§Staten Island
state§NY
zip§10305
country§United States
phone§917 533 1469
website§https://www.acurxpharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.
fullTimeEmployees§4
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Robert J. DeLuccia', 'age': 77, 'title': 'Co-Founder & Executive Chairman', 'yearBorn': 1946, 'fiscalYear': 2022, 'totalPay': 677186, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David P. Luci CPA, Esq., J.D.', 'age': 56, 'title': 'Co-Founder, President, CEO, Corporate Secretary & Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 655000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert G. Shawah CPA, CPA', 'age': 56, 'title': 'Co-Founder & CFO', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 375000, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-1.807
currency§USD
dateShortInterest§1702598400
forwardEps§-0.83
exchange§NCM
quoteType§EQUITY
shortName§Acurx Pharmaceuticals, Inc.
longName§Acurx Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1624627800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f968c125-b6b8-3075-a306-c4b0f5d5bed0
gmtOffSetMilliseconds§-18000000
targetHighPrice§14.0
targetLowPrice§10.0
targetMeanPrice§12.67
targetMedianPrice§14.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§2.188
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
